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Rectal cancer and tumor regression grading: A multiinstitucional experience
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Introduction. Neoadjuvant chemoradiotherapy for locally advanced rectal cancer has been shown to decrease rates of local recur-
rence. There is now compelling evidence that pathological complete response is an independent predictor of local recurrence,
distal metastases, disease-free and overall survival .The purpose of this review is to highlight tumour regression grading in our
patients with rectal cancer.
Methods. From 2010 to 2012 120 patients were treated in our institution with rectal cancer, only 76 of them were eligible for this
study. All of them were treated with long-course neoadjuvant chemoradiation. Patients received different 5FU based chemother-
apy regimens. Radiation therapy was administrated to the pelvic volume to a dose of 45Gy and boost over primary tumor of
5.4Gy (total dose to 50.4Gy) employing 3D-CRT. We used Dworak tumor regression system for rectal cancer.
Results. All patients have completed neoadjuvant treatment and underwent surgical procedures. 30% of patients had complete
response in the bowel wall (ypT0). Of the remaining 51 patients who had residual cancer cells, 35.5% were Gr3, 16.5% were GR2,
16.5% were GR1, only one patient were GR0. With a follow up of 20 months 88% patients are DFS, 9% have developed distant
metastases and 1.3% (1 patient) have developed local recurrence.
Conclusion. This study demonstrates the feasibility of preoperative chemoradiotherapy with a high pCR rate, comparable with
previously reported. Longer follow-up is needed to analyze if the regression degree has inﬂuence on DFS and OS.
http://dx.doi.org/10.1016/j.rpor.2013.03.217
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Introduction. Total mesorectal excision (TME) decreases local recurrence of rectal cancer, and preoperative radiotherapy is also
beneﬁcial for local control.Weevaluate the results after the combinedpreoperative treatment inpatients (p)with locally advanced
resectable rectal cancer treated in our hospital.
Objective. We have analysed 161 p with rectal cancer T3–T4 (assessed by endoanal ultrasound CT and in later years MRI)
treated with RT3DC (45–50.4Gy/1.8Gy fraction) and concomitant chemotherapy with (Xeloda 850mg/daily in 53.4% or Tega-
fur 1200mg/daily in 38.5%), followed by surgery after 6–8 weeks. Later on 70.2% received adjuvant chemotherapy based on XELOX
(Xeloda/IMPACT/FOLFOX/De Gramont/Mayo/5-FU+AF) iv according to protocol.
Materials and methods. From January 2003 to December 2010 we treated 108 men and 53 women. Median age 66 years (range 27-80)
Initial state: uT3: 146 p/uT4: 13 p/N+: 49 (30.4%). Tumor <6 cm from the anal margin, 77 p (47.8%), >6 cm 81 (50.3%). The surgery
consisted of: abdominoperineal resection 71 p (44.1%), (anterior) resection 79 p (47.8%), endoanal resection 1 p (0.6), and exclusive
colostomy by frozen pelvis 1 p (0.6). We did not record a signiﬁcant increase in complications occurring during surgery. We
obtained a “downstaging” of tumors in 88 p (54.7%) including 25 p (15.5%) with pathological complete response. The post surgery
pathologic anatomy was 50.9% well-differentiated adenocarcinoma, 25.5% moderately differentiated, 9% undifferentiated. There
was locoregional recurrence in 9 p, and 19 p have relapsed with time. Of them 119 p remain disease free, 9 live with the illness,
10 died of other causes, and 17 died of recurrence. Overall survival has been 78,6% with an actuarial follow up of 114 months.
The survival free of recurrence has been 67.8% with an actuarial follow up of 117 months.
Conclusions. Preoperative radiochemotherapy increases the local control with amanageable toxicity proﬁle, obtaining good results
and diminution of previous stage and surgery and also survival.
http://dx.doi.org/10.1016/j.rpor.2013.03.218
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Introduction. The management of rectal cancer has undergone a radical change during the last years. Several studies have
shown a reduction in recurrence and toxicity in patients treated with concomitant preoperative chemoradiotherapy compared
to postoperative treatment, as well as a survival increased.
Objective. To analyze the results of our experience in the treatment of rectal cancer stage II and III with neoadjuvant chemora-
diotherapy, to know the efﬁciency in terms of toxicity, recurrence and survival.
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Materials and methods. A retrospective study has been realized reviewing the clinical histories of 211 patients diagnosed of rectal
adenocarcinoma treated with neoadjuvant chemoradiotherapy between January 2001 and December 2010. The patients received
a dose between 45 and 50.4Gy with external radiotherapy in concomitance with chemotherapy based on ﬂuoropirimidinas.
Results. Of the 211 patients, 144 were men and 67 women, with a mean age of 62 years (30–85). Data obtained on the acute toxicity
are: cutaneous: G0: 56.8%; G1: 19.4%; G2: 15.1%; G3–4:7.1%. Genitourinary: G0: 79.6%; G1: 15.6%; G2: 3.3%; G3–4: 0%. Rectal: G0:
68.2%; G1: 20.8%; G2: 7.6%; G3–4: 2.4%. Gastrointestinal: G0: 55.9%; G1: 21.3%; G2: 14.2%; G3–4: 7.6%. Hematologic: G0: 86.2%; G1:
6.2%, G2: 2.4%, G3–4: 1.9%. 25% of patients developed late toxicity, the most frequent are intestinal obstruction and incontinence.
Relapses: 18 patients local recurrence (8.5%), 49 distant metastases (23.2%) and 12 both levels (5.7%). 15 patients had a second
tumor (7.1%). After 54 months of follow-up (3–141), overall survival was 76±5% and free survival of disease was 69±6%.
Conclusion. The results are comparable to data reported in the literature and as demonstrated in several studies, the preoperative
treatment produces a decrease of the local anddistant recurrence comparedwith postoperative treatment and survival increased.
Also, the treatment tolerance has been good and we only ﬁnd low percentage of toxicity in all grade.
http://dx.doi.org/10.1016/j.rpor.2013.03.219
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Introduction. INT-0116 study showed improvement in terms of disease free survival and overall survival using a scheme of adjuvant
chemoradiotherapy. To date, this is the standard adjuvant treatment after surgery in locally advanced gastric cancer. PURPOSE
To evaluate toxicity (RTOG scale), disease free survival (DFS), recurrence free survival (RFS) and overall survival (OS) in patients
treated with schema QT/RT in our department.
Materials and methods. Retrospective analysis of 67 patients diagnosed of gastric carcinoma and treated between October 2002
and June 2012 at “Hospital Reina Sofía” in Cordoba (Spain). Scheme of treatment: 5 cycles of chemotherapy (5-Fu/Leucovorin)
and concomitant radiotherapy (45Gy at 180 cGy/fraction) with second and third cycles. We hereby present a descriptive analysis
and survival analysis using Kaplan-Meier method. Statistic SPSS program (V10).
Results. Mean age: 61 (35–79), 75% males, 25% females. Epigastric pain was the most frequent symptom (39%) at diagnosis. Total
gastrectomy performed in 49% of patients and partial gastrectomy in 51%. The most frequent location was antrum (56.7%). Stage
distribution: IB: 4.5%, IIA: 40.3%, IIB: 9%, IIIA: 31.3%, IIIB: 9%, IV: 5%.Margins R0 in 78% andR1 in 22%. 90%of patients completed the
full treatment. Maximum toxicity recorded during concomitant treatment: Digestive G2: 28.4%, Esophagus G3: 1.5%, Leucopenia
G2: 15%, Thrombocytopenia G2: 1.5% and skin G1: 4.5%. Median follow-up was 35 months (2 - 126). OS at 3 and 5 years: 54% and
48% respectively. DFS in the same periods: 60% and 53%. 36% patients had loco-regional disease recurrence and metastases. RFS
at 3 and 5 years: 74% and 65% respectively. Median OS: 51.7% (95% CI: 12–91).
Conclusions. Chemoradiotherapy treatment for locally advanced gastric carcinoma provides good results in terms of DFS, RFS and
OS with good tolerance. Our results are similar to those described in the literature.
http://dx.doi.org/10.1016/j.rpor.2013.03.220
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Introduction. A preoperative treatment choice of rectal cancer is short-course (SC) radiotherapy (RT). In recent researches, it has
been observed that superior intervals of time to surgery seem to relate with a greater complete pathological response rate.
Objectives. Determine the existent relationship between the time until surgery with the pathological response grade (PRG). Meth-
ods: A series of 20 patients is analyzed retrospectively, collected from May/2009 until December/2012, diagnosed with rectal
adenocarcinoma (stages II and III) that received preoperative SC radiotherapy (25Gy/500 cGy session). The data was analyzed
with the statistical program SPSS v.15. The Ryan’s modiﬁed scale was used for the PRG valuation.
Results. The age rank was from 43 to 90 years (media: 76.5). 16 (80%) were of the male sex, 80% (16) correspond to T3 and 65% (13)
were N+. 7 (35%) received 1 cycle of chemotherapy pre and/or post radiotherapy and 13 (65%) radiotherapy exclusively. Regarding
to the type of surgery: Anterior resection in 10 (50%), abdominoperineal amputation in 9 (45%) and local excision in 1 (5%). The
time rank pass until surgery was from 2 to 15 weeks (median: 5 weeks). The PRG was 5 (25%), 11 (55%) and 4 (20%) for grade 1, 2
and 3 respectively. There was not grade 0. The 17% relapsed locally in the ﬁrst year. After a follow-up median of 16 months, 83%
kept free of relapses until the end of the research or until the patient decease. The local survival at 3 years was of 20%. There is
no statistical correlation between the waiting time until surgery >5 weeks and a better pathological response (p=0.57).
